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AbstrAct
background and objective Atrial fibrillation (AF) is common 
and causes impaired quality of life, an increased risk of 
stroke and death as well as frequent hospital admissions. The 
majority of patients with AF require control of heart rate. In this 
article, we summarise the limited evidence from clinical trials 
that guides prescription, and present the rationale and protocol 
for a new randomised trial. As rate control has not yet been 
shown to reduce mortality, there is a clear need to compare 
the impact of therapy on quality of life, cardiac function and 
exercise capacity. Such a trial should concentrate on the long-
term effects of treatment in the largest proportion of patients 
with AF, those with symptomatic permanent AF, with the aim of 
improving patient well-being.
Design and intervention The RAte control Therapy 
Evaluation in permanent Atrial Fibrillation (RATE-AF) trial 
will enrol 160 participants with a prospective, randomised, 
open-label, blinded end point design comparing initial 
rate control with digoxin or bisoprolol. This will be the 
first head-to-head randomised trial of digoxin and beta-
blockers in AF.
Participants Recruited patients will be aged ≥60 years 
with permanent AF and symptoms of breathlessness 
(equivalent to New York Heart Association class II 
or above), with few exclusion criteria to maximise 
generalisability to routine clinical practice.
Outcome measures The primary outcome is patient-
reported quality of life, with secondary outcomes including 
echocardiographic ventricular function, exercise capacity 
and biomarkers of cellular and clinical response. Follow-up 
will occur at 6 and 12 months, with feasibility components 
to inform the design of a future trial powered to detect a 
difference in hospital admission. The RATE-AF trial will underpin 
an integrated approach to management including biomarkers, 
functions and symptoms that will guide future research into 
optimal, personalised rate control in patients with AF.
Ethics and dissemination East Midlands-Derby 
Research Ethics Committee (16/EM/0178); peer-reviewed 
publications.
trial registration  Clinicaltrials. gov: NCT02391337; 
ISRCTN: 95259705. Pre-results.
IntrODuctIOn
Atrial fibrillation (AF) is a common cause 
of stroke and cardiovascular death, leads to 
poor quality of life and doubles the risk of 
hospital admission.1 We are currently in the 
midst of an epidemic of AF, with both inci-
dence and prevalence expected to double in 
the next 20 years.2–4 Although AF can affect 
any age group, patients are typically elderly 
with significant comorbidities, including 
up to 50% suffering from heart failure.5 AF 
is both a cause and consequence of heart 
failure, with complex interactions leading 
to impairment of systolic and diastolic 
function.6 7 The combination of these two 
conditions is expected to have a dramatic 
impact on the burden of healthcare world-
wide.8–11
Management of AF involves antico-
agulation to prevent strokes, selecting 
appropriate patients for restoration of 
sinus rhythm and almost universal need for 
control of heart rate. In contrast to other 
management strategies, the choice of rate 
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Protocol
strengths and limitations of this study
 ► Control of heart rate is universally used in patients 
with atrial fibrillation  (AF), but evidence from good 
quality randomised controlled  trials is extremely 
limited.
 ► Despite common clinical use, there has never been 
a direct randomised comparison of beta-blockers 
and digoxin for heart rate control in patients with AF 
(with or without heart failure).
 ► The RAte control Therapy Evaluation in permanent 
Atrial Fibrillation (RATE-AF)  trial will assess the 
effect of therapy on patient-reported quality of life, 
and improve methods to capture this information in 
patients with AF. The trial will also evaluate the long-
term impact on cardiac function, define reproducible 
methods to measure systolic and diastolic function in 
AF and develop new biomarkers for personalisation 
of treatment.
 ► The trial will not have the power to identify 
differences in clinical events, but will allow us to 
plan a future trial designed to detect a difference in 
the need for admissions to hospital.
group.bmj.com on December 13, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Kotecha D, et al. BMJ Open 2017;7:e015099. doi:10.1136/bmjopen-2016-015099
Open Access 
Figure 1 Evidence-based summary for management of atrial fibrillation. Summary of evidence for main components of clinical 
management, highlighting paucity of robust data for key issues regarding rate control therapy. RCT, randomised controlled trial; 
LV, left ventricular; NOAC, novel oral anticoagulants.
control therapy has a very low-quality evidence base 
(figure 1).12 Guidelines from the National Institute for 
Health and Care Excellence and the European Society 
of Cardiology (ESC) have mandated further research 
specifically on rate control,1 13 which is also reflected 
in the level of recommendations from the American 
Heart Association.14 The small studies currently avail-
able are often uncontrolled or with short follow-up,15–19 
providing few insights on the biological effects of treat-
ment or the mechanisms underpinning the response to 
therapy. With no evidence for any impact of rate control 
on mortality,20 21 and limited data for any difference in 
quality of life or functional outcomes, the choice of rate 
control agent is currently informed by expert consensus 
and physician experience.
In this paper, we review the current evidence-base for 
rate control in AF and the rationale for a new randomised 
controlled trial (RCT). The RAte control Therapy Eval-
uation in permanent Atrial Fibrillation (RATE-AF) trial 
will compare initial therapy with beta-blockers versus 
digoxin in older patients with symptomatic permanent 
AF, assessing quality of life, functional capacity, left-ven-
tricular ejection fraction (LVEF), diastolic function and 
biomarkers of treatment response.
rationale for a new trial of rate control in AF
Why not choose a rhythm control strategy?
A number of RCTs have assessed the addition of rhythm 
control strategies to control of heart rate in patients with 
AF, most often with anti-arrhythmic drugs (AAD) and 
direct current cardioversion. Neither of the two largest 
trials found any difference in clinical outcomes comparing 
these approaches (Atrial Fibrillation Follow-up Inves-
tigation of Rhythm Management (AFFIRM) and Rate 
Control versus Electrical Cardioversion for Persistent 
Atrial Fibrillation (RACE)) .22 23 Other smaller trials and 
meta-analyses have confirmed that rhythm control is not 
superior to regulation of heart rate alone,24–26 including 
heart failure patients with both impaired and preserved 
ejection fraction.27 28 These studies have analysed hetero-
geneous populations, including both paroxysmal and 
permanent AF that may differ with regard to mechanism, 
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Figure 2 Hospitalisation in rate vs rhythm control trials. Meta-analysis of hospitalisation in the six largest rate vs rhythm control 
trials, excluding hospital visits for cardioversion procedures, where applicable. Studies are pooled with a random-effects model. 
Significant heterogeneity was identified, with an I2 value of 66.8% (p=0.01). Grey boxes represent the comparative weight of 
the study. STAF, Strategies of Treatment of Atrial Fibrillation study (cardioversion/AAD vs rate control in persistent AF)76; PIAF, 
Pharmacological Intervention in Atrial Fibrillation trial (amiodarone/cardioversion vs diltiazem in persistent AF)77; HOT CAFE, 
How to Treat Chronic Atrial Fibrillation study (cardioversion/AAD vs rate control in persistent AF)78; AF-CHF, Atrial Fibrillation 
and Congestive Heart Failure trial (cardioversion/AAD vs rate control in paroxysmal/persistent AF with LVEF ≤35%)27; CRAAFT, 
Control of Rate vs Rhythm in rheumatic Atrial Fibrillation Trial (cardioversion/amiodarone vs diltiazem in persistent AF due to 
rheumatic heart disease)79; AFFIRM, Atrial Fibrillation Follow-up Investigation of Rhythm Management study (AAD/cardioversion 
versus rate control in paroxysmal/persistent AF); AAD, anti-arrhythmic drugs; LVEF, left-ventricular ejection fraction.22
prognosis and the response to treatment.15 However, 
there is also evidence that a rhythm control strategy may 
increase hospital admissions. A meta-analysis of major 
published trials is presented in figure 2, highlighting a 
17% increase in the risk of hospitalisation in the rhythm 
control group (after exclusion of hospital visits related 
to cardioversion). Although limited by patient crossover 
and the association between AAD and adverse events,29 
the results highlight the importance of trials comparing 
different rate control options and associated healthcare 
costs.
Although AF ablation is becoming increasingly popular, 
it remains a highly invasive method to restore sinus 
rhythm.30 31 Current guidelines recommend ablation to 
improve AF-related symptoms in patients with paroxysmal 
AF, or as a treatment option in symptomatic persistent AF 
that is refractory to other therapy.1 14 Long-term outcome 
studies are awaited and need to be balanced against 
procedural complications and AF recurrence. Even in 
patients receiving intensive rhythm control therapy, rate 
control is often necessary to reduce symptoms during AF 
paroxysms. Furthermore, 40%–50% of patients with AF 
are deemed as unsuitable for rhythm control (permanent 
AF),5 32 and are maintained on rate control therapy to 
reduce potential symptoms and avoid tachycardia that 
may worsen ventricular function.6 Patients with perma-
nent AF have a higher residual risk of cardiovascular 
death, stroke or systemic embolism, despite anticoagula-
tion.33
What is the optimal heart rate target in AF?
There is clinical uncertainty about how to control heart 
rate and the intensity of rate-reduction. In the RACE II 
trial of 614 randomised patients with permanent AF, there 
were no benefits of strict (<80 bpm at rest) compared with 
lenient rate control (resting heart rate <110 bpm) over 3 
years of follow-up.34 Although interpretation was limited 
by the narrow difference in heart rate between groups, 
lenient rate control was found to be non-inferior with 
an adjusted HR of 0.80 (90% CI 0.55 to 1.17) for a wide 
composite of adverse clinical outcomes (12.9%, compared 
with 14.9% in the strict control arm). In addition, there 
were no differences in symptoms or New York Heart Asso-
ciation (NYHA) class,34 35 and patients achieving strict 
rate control required more clinic visits.36 These findings 
are consistent with other trials,37–39 registries32 and even 
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randomised40 and observational41 cohorts in patients with 
concomitant heart failure, suggesting that intensity of 
heart rate control is not the key determinant of outcomes 
in AF.
Do outcomes vary with different rate control therapies?
Medical therapy to achieve rate control in AF can be 
achieved with beta-blockers, digoxin and non-dihydrop-
iridine calcium channel blockers (CCB; diltiazem or 
verapamil).1 Only a limited evidence-base is available 
to assist clinicians in choosing first-line and subsequent 
therapy, resulting in wide variations in clinical prac-
tice42–44 and frequent use of combination therapy. 
Guidelines suggest the choice of medication should be 
individualised, dependent on the presence of ongoing 
symptoms.1 14 However, these recommendations are 
based on low-quality trials and observational data, often 
with small numbers of participants and follow-up over a 
few weeks.16 There are no RCTs comparing long-term rate 
control options in AF.
Demonstrating any reduction in hard clinical outcomes 
with rate control has proved elusive. In patients with heart 
failure, reduced ejection fraction and concomitant AF, 
an individual patient-level meta-analysis of double-blind 
RCT data has suggested that beta-blockers do not reduce 
all-cause mortality or hospital admissions compared with 
placebo,20 in contrast to the substantial benefit seen in 
sinus rhythm.45 Similarly, the use of digoxin was not asso-
ciated with any increase, or reduction, in mortality in a 
comprehensive systematic review.21 This finding deviates 
from prior observational analyses which are confounded 
by the fact that sicker patients tend to receive digoxin 
more often, which can only be addressed within a 
randomised trial. Although digoxin is known to reduce 
hospital admissions in patients with heart failure and 
reduced ejection fraction in sinus rhythm,46 the impact in 
patients with AF is unknown.
If rate control has limited effect on mortality, what 
about evidence for a differential effect on other outcomes, 
such as functional capacity, cardiac function or quality 
of life? Beta-blockers are the most commonly used 
rate control agents and although they have a greater 
impact than digoxin on heart rate during exertion, 
there is no evidence that this results in better exercise 
capacity.17 18 47–49 Beta-blockers were not associated with 
any improvement in arrhythmia-related symptoms in a 
small RCT of 60 low-risk patients with permanent AF, 
compared with diltiazem and verapamil which reduced 
the frequency of symptoms.50 Those in the beta-blocker 
group had a reduction in exercise capacity and increase 
in B-type natriuretic peptide (BNP) compared with those 
treated with CCB.51 Analysis of smaller trials comparing 
beta-blockers with CCB are inconsistent.17Compared 
with verapamil or diltiazem, digoxin has less effect on 
heart rate but there is no consistent evidence for any 
difference in functional outcomes.17 18 47 49 52 Importantly, 
diltiazem and verapamil are usually avoided in patients 
with reduced ejection fraction due to the risk of adverse 
outcomes,53–57 leaving only beta-blockers or digoxin as 
suitable therapy. Only a single RCT has been published 
comparing beta-blockers with digoxin in patients with AF 
and heart failure (mean LVEF 24%, n=47).58 Although 
there was a marginally significant improvement in LVEF 
with combined carvedilol/digoxin versus placebo/
digoxin, blinded withdrawal of digoxin then led to a 
deterioration in LVEF, accompanied by an increase in 
BNP. The direct effects of digoxin on LVEF and diastolic 
function have only been studied in patients with sinus 
rhythm, where digoxin increased LVEF by 3%–11% and 
improved diastolic filling.59–61 Magnesium has been 
shown to complement digoxin therapy to achieve lower 
ventricular rates in AF,62 but is not in common use due to 
the availability of beta-blockers and CCB which are more 
potent agents for acute heart rate control.1 Although 
data on patient-reported quality of life are limited,63 64 
rate control has been associated with improved quality 
of life in trials assessing rate versus rhythm control.65–67 
The mechanism by which rate control therapy mediates 
an increase in physical functioning and quality of life is 
unknown but conceivably due to improvements in LVEF 
and/or diastolic function.
In summary, rate control is an important part of treat-
ment in all patients with AF but the evidence-base is poor, 
particularly in those with permanent AF who form the 
majority of patients in clinical practice. Rate control in AF 
is also subject to considerable, and poorly characterised 
individual variability in response, with limited informa-
tion about the effects of therapy on cardiac function, 
quality of life and functional capacity.
the rAtE-AF trial
The RATE-AF trial is the first head-to-head randomised 
assessment of beta-blockers versus digoxin as the initial 
rate control agent in patients with AF. The trial has a 
prospective, randomised, open-label, investigator-blinded 
end point (PROBE) design, and is planned as an inclu-
sive study that reflects and will have an important impact 
on clinical practice (box 1). The primary outcome is 
patient-reported quality of life using the Short Form (36) 
Health Survey (SF-36) physical component summary score 
at 6 months’ post-randomisation. The major secondary 
outcomes are change in LVEF and diastolic function on 
echocardiography, functional capacity, global and AF-spe-
cific quality of life and cardiovascular biomarkers (box 2). 
A key objective of the trial is to improve the methods used 
for measuring quality of life in patients with AF, as well 
as optimising the validity, reproducibility and acquisi-
tion of echocardiographic left-ventricular function. The 
RATE-AF trial will also act as a feasibility study to plan a 
future, event-driven clinical trial exploring the impact of 
different rate control strategies on cardiovascular events 
and unplanned hospital admissions. The study is spon-
sored by the University of Birmingham and funded by the 
National Institute for Health Research (NIHR), as part of 
a Career Development Fellowship awarded to the Chief 
Investigator (DK).
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box 1 the rAte control therapy Evaluation in permanent 
Atrial Fibrillation (rAtE-AF) trial—information for patients
About atrial fibrillation
Atrial fibrillation is a common heart condition that leads to an irregular 
and often rapid heart rate. Atrial fibrillation causes 1 in 4 strokes, and 
patients have frequent hospital admissions and a higher risk of dying. 
In addition, atrial fibrillation makes many patients feel unwell, with 
reduced quality of life.
What is the purpose of the trial?
Atrial fibrillation usually requires medication to control heart rate, but 
we currently do not know which medication is better for patients. The 
aim of this study is to find out which of the two treatments improves 
quality of life and the function of the heart, digoxin or bisoprolol (a 
beta-blocker).
What will happen in the trial?
The RATE-AF trial is designed to compare two approaches for control 
of heart rate, based on initial treatment with either digoxin or beta-
blockers, medications which are commonly used by doctors. The main 
objective of the trial is to research the effects of treatment on quality of 
life in patients with atrial fibrillation . We will also test whether quality 
of life questionnaires respond to changes in symptoms experienced by 
patients, how we use ultrasound to look at the function of the heart, 
and develop new markers in the blood to personalise treatment.
More information
RATE-AF trial video: https://www.youtube.com/watch?v=4oxe8AcVo0E 
or search ‘rateaf’ in YouTube.




Inclusion criteria are patients aged 60 years or older with 
breathlessness (equivalent to NYHA class II or more) 
and permanent AF, characterised as a physician deci-
sion for rate control with no plans for cardioversion, 
AAD or ablation therapy. Only limited exclusion criteria 
apply (figure 3), reflecting any clear requirements or 
contraindications for either beta-blockers or digoxin. As 
neither agent impacts on mortality in patients with heart 
failure,20 21 reduced LVEF is not an exclusion criterion. All 
patients are expected to be anticoagulated if appropriate, 
according to their clinical risk of stroke and thromboem-
bolism.
study procedures and outcomes
One hundred and sixty eligible patients in need of rate 
control will be invited to participate in the study from 
primary and secondary care across two major NHS Trusts 
in Birmingham, UK. The RATE-AF trial is managed 
by the Birmingham Clinical Trials Unit (University of 
Birmingham) and situated within the Birmingham 
NIHR/Wellcome Trust Clinical Research Facility.
Following written informed consent, participants will be 
randomised in a 1:1 ratio to either bisoprolol or digoxin 
therapy. Randomisation will be provided by a comput-
er-generated minimisation algorithm to ensure balance 
between the treatment arms for baseline European Heart 
Rhythm Association class and gender. Allocation will 
be concealed until the patient has been recruited and 
consented, thereafter the trial will be open-label.
Baseline assessment procedures will include patient-re-
ported quality of life questionnaires (table 1), 6 min walk 
distance, echocardiography and biomarker assessment. 
Participants will then receive study medication (bisopr-
olol 1.25–15 mg once daily or low-dose digoxin 62.5–250 
μg once daily), with scheduled uptitration visits to attain a 
heart rate at rest of ≤100 bpm. This heart rate is in line with 
international recommendations1 and was chosen prag-
matically to reflect the opinion of many cardiologists that 
tachycardia can lead to, or worsen, systolic and diastolic 
dysfunction. Ambulatory 24 hours ECG monitoring will be 
performed at the end of uptitration (unblinded). Inves-
tigator-blinded end points will be assessed at the interim 
(6-month) and final (12- month) visit, which include 
patient-reported quality of life, echocardiographic param-
eters of systolic and diastolic left-ventricular function and 
biomarker assessment (figure 3).
Exploratory work and clinical practice improvement
During the trial, qualitative research using focus groups 
and structured interviews will assess whether the quality 
of life questionnaires adequately and acceptably assess 
changes in symptom burden in a sample of patients 
from each treatment arm. We will also compare and 
contrast the generic and AF-specific questionnaires. 
The aim of this work is to improve the methods used 
for measuring patient-reported outcomes in AF, and to 
address some of the limitations we have identified in 
published validation studies.68
Optimal acquisition of echocardiography in patients with 
AF will be determined by reproducibility studies, comparing 
repeated measures of systolic/diastolic function according 
to cardiac cycle length. The RATE-AF trial will address the 
evidence gaps we have identified in a systematic review of 
echocardiography in patients with AF,69 and explore the 
diagnostic difficulty of categorising heart failure in the 
context of AF (particularly with preserved ejection fraction, 
where symptom classification is confounded and BNP levels 
are consistently raised due to AF.7
Blood samples from participants will be analysed for 
the cellular effects of rate control, including intracellular 
sodium, calcium and endogenous cardiotonic steroids 
(CTS) using photometry in cultured human cardiomy-
ocytes. This work will give mechanistic insight into the 
cellular response to beta-blockers and digoxin, identify 
novel markers of treatment effect and develop assays 
that are more robust than serum digoxin concentration 
(SDC) for determining individual patient dosage. SDC is 
an immunoassay known to be a poor marker of digoxin 
toxicity,70 which can cross-react with other targets71 (eg, 
endogenous CTS). Although SDC will be performed at 
6 months follow-up and as required during the trial to 
advise clinicians on dose and avoid high digoxin levels, 
digoxin toxicity remains a clinical diagnosis at present. 
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box 2 Outcomes and objectives of the rAte control therapy Evaluation in permanent Atrial Fibrillation (rAtE-AF trial
Primary outcome:
Comparison of two strategies for rate control on patient-reported quality of life, based on initial use of digoxin vs beta-blocker therapy, with a 
predefined focus on physical well-being using the SF-36 physical component summary at 6 months.
secondary outcomes:
 ► Patient reported quality of life at 6 and 12 months, including SF-36 global and domain-specific scores, EQ-5D-5L summary index and visual analogue 
scale, and AFEQT overall score.
 ► Echocardiographic left-ventricular function at 12 months, including LVEF and diastolic function (E/e’ and composite of diastolic indices).
 ► Functional assessment at 6 and 12 months, including 6 min walking distance and change in EHRA class.
 ► Change in NT-proBNP levels at 6 months.
 ► Change in heart rate from baseline and group comparison using 24 hours ambulatory ECG at end of uptitration.
Feasibility assessment:
 ► Successful methods for recruitment across primary and secondary care.
 ► Key issues that affect retention of participants, such as convenience, compliance and cross-over.
 ► Drug discontinuation rate and adverse reactions leading to drug discontinuation.
 ► Therapy-induced requirement for additional treatment (eg, pacemaker implantation).
 ► Population-specific SD and proportions to enable sample size calculation for a future trial.
 ► Assessment of unplanned hospital admissions and cardiovascular outcomes.
Exploratory objectives:
 ► Assessment of the validity and reproducibility of echocardiographic measures in patients with AF.
 ► Correlation of baseline measures, including quality of life questionnaires and unblinded baseline investigations such as quality of life, NT-proBNP, 
LVEF, E/e’, EHRA class, intracellular biomarkers and heart rate.
 ► Impact of therapy on intracellular sodium and calcium concentration and cardiotonic steroid levels as biomarkers of cellular response.
 ► Impact of combination therapy on outcomes.
 ► Change in cognitive function at 12 months.
 ► Qualitative research of patient-reported quality of life using focus groups to explore patient acceptability, optimal delivery methods and responsiveness.
 ► Correlation of serum digoxin concentration with change in quality of life and intracellular methods.
 ► Cost-consequence economic analysis from an NHS healthcare perspective.
AF, atrial fibrillation; AFEQT, Atrial Fibrillation Effect on QualiTy of life questionnaire; NT-proBNP, N-terminal pro B-type natriuretic peptide; EHRA, European Heart Rhythm 
Association functional class; EQ-5D-5L, EuroQol five dimensions five level questionnaire; LVEF, left ventricular ejection fraction; NHS, National Health Service; SF-36, Short 
Form (36) Health Survey.
Serum will also be stored for the development of new 
blood-based and genetic biomarkers that aid in personal-
isation of rate control therapy.
statistical considerations
The null hypothesis is of no difference in the physical func-
tioning domain of the SF-36 quality of life questionnaire 
when comparing a strategy of digoxin versus beta-blocker 
therapy for initial rate control in older patients with 
permanent AF. The alternative hypothesis is superiority 
of one over the other therapy as an initial strategy of 
care. Randomising 144 patients we can assume an 85% 
power to detect an effect size of half a SD in a continuous 
outcome measure of quality of life (two-sided α of 0.05). 
Assuming that 10% of patients will be lost to follow-up, 
160 patients are needed. There is some evidence from 
existing research to support the notion that the treatment 
effect could be this large. This includes a 17% improve-
ment in SF-36 role-physical score in the rate control arm 
of the RACE study,66 a 22% improvement in a proprietary 
symptom-checklist with CCB (compared with 8% change 
in those assigned beta-blockers),19 and 17% improve-
ment with rate control using SF-36 in the PIAF trial.67 The 
RATE-AF trial will also help us to explore surrogates for 
clinical outcomes, such as LVEF using echocardiography 
and BNP, and provide estimates for a future definitive 
trial of rate control in AF, including reliable information 
on recruitment rates, study drug titration, cross-over, 
retention and healthcare costs.
trial oversight, management and registration
RATE-AF will be conducted in accordance with guidelines 
for Good Clinical Practice (GCP) and the Declaration of 
Helsinki, and has regulatory approval from the Medicines 
and Healthcare products Regulatory Agency.
Oversight will be provided by a Trial Steering Committee, 
comprising an independent Data Monitoring Committee 
and members of the RATE-AF Trial Management Group. 
This includes representatives of the patient and public 
involvement panel, involved in both the design and 
management of the trial. A Clinical Events Committee 
will be formed to adjudicate on adverse events.
The RATE-AF trial is registered at  Clinicaltrials. gov 
(NCT02391337), ISRCTN (95259705) and EudraCT 
(2015-005043-13). Further information can be obtained 
from the trial website, http://www. birmingham. ac. uk/ 
rate- af, and the trial protocol (see online supplementary 
material). The protocol was developed in accordance 
with the Standard Protocol Items for Randomized Trials 
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Figure 3 The  RAte control Therapy Evaluation in permanent Atrial Fibrillation (RATE-AF) trial schema. Trial flow chart, including 
major end points and inclusion/exclusion criteria.
Table 1 Patient-reported quality of life questionnaires used in RAte control Therapy Evaluation in permanent Atrial Fibrillation
Questionnaire Details Advantages and disadvantages
Short Form (36) 
Health Survey80
Generic instrument with 4-week recall period in eights 
domains (vitality, physical functioning, bodily pain, 
general health perceptions, physical role functioning, 
emotional role functioning, social role functioning and 
mental health)
11 subdivided questions, each recorded with a Likert 
scale
Scoring: each response is given a numerical value (0–
100, with 100 representing the best level of functioning 
possible), which are averaged across each domain
Extensively validated across a wide variety of 
conditions and the elderly81
Not specific to AF and hence other comorbidities 
may dominate responses





Generic instrument about today’s health with a five-
answer scale in five domains (mobility, self-care, usual 
activities, pain/discomfort and anxiety/depression)
Scoring: each question is scored (1–5, with 1 
representing the best health). The overall profile can 
be indexed to country-specific value sets giving a 
continuous value
Also includes a visual analogue scale denoting current 
health perception (0–100 scale, with 100 representing the 
best health the patient can imagine)
Simple questionnaire that is quick to complete 
and includes a visual scale
Extensive utilisation, particularly for heath 
economic assessment, with improvement 
discrimination over prior versions84




QualiTy of life 
questionnaire85
AF-specific quality of life instrument with 4-week recall 
period in domains relating to symptoms, daily activities 
and treatment
20 questions (18 on health-related quality and life and 2 
on treatment satisfaction), each recorded with a 7-point 
Likert scale
Scoring: responses to the 18 questions are summed 
and converted to a continuous score (0–100, with 100 
corresponding to no patient concerns nor disability due 
to AF) Component domains are scored in a similar way
Specific to the impact of AF on quality of life
Better than other AF-specific tools in a 
systematic review of methodological/
psychometric assessment68
Limited validation as yet in comparison with 
generic tools,86 87 particularly for clinical 
responsiveness
Licence fee may apply
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statement,72 and the latest guidance from the Interna-
tional Society for Quality of Life Research Best Practice 
taskforce.73–75 
Ethics and dissemination
The trial has ethical approval from the East Midlands—
Derby Research Ethics Committee (16/EM/0178) 
and approval from the National Health Service Health 
Research Authority (IRAS project ID: 191437).
The research findings will be submitted for publication 
to peer-reviewed journals after review by the oversight 
committees and the Patient Involvement Panel, and 
presented to relevant national and international meet-
ings. Trial participants will be sent a lay summary of the 
final results of the trial, written by the Patient Involve-
ment Panel.
cOnclusIOn
Defining appropriate rate control therapy is vital, partic-
ularly in the rapidly growing number of older patients 
with permanent AF, where current evidence is extremely 
limited. Rate control is an integral part of management 
in almost all patients with AF, but hardly any controlled 
trial evidence exists to guide the choice of agents. This 
is unacceptable in light of the potential benefits and 
possible adverse effects of treatment. In addition, the 
complete lack of data on the impact of medical therapy 
on symptom burden and heart function necessitate 
a programme of reproducibility and validity of both 
patient-reported quality of life and cardiac imaging in 
AF. The RATE-AF trial will answer key clinical questions 
about how to initiate therapy in order to improve patient 
well-being, stratified by relevant patient characteristics 
such as baseline symptoms, systolic and diastolic cardiac 
function, and biomarkers of treatment effect.
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